$FBLG

FibroBiologics (NASDAQ:FBLG) announced its patent portfolio has grown to 170 issued patents, up from 124 at the end of 2025. The biotech company's patents cover various therapies, including wound healing, diabetes, and cancer. CEO Pete O’Heeron highlighted the expansion, which now includes over 325 issued and pending patents worldwide. The company focuses on fibroblast-based therapeutics and has over 150 patent applications pending.

FibroBiologics (FBLG) will report Q3'26 earnings on November 17, with estimated revenue of 0 USD and EPS of (0.63) USD. Details available on FBLG's Financials page.

FibroBiologics (FBLG) received a European patent for fibroblast-based cancer treatment methods. The patent covers modifying fibroblasts to deliver anti-cancer agents, like oncolytic viruses, to tumors. The company claims this strengthens its IP portfolio and supports its cancer research. FibroBiologics has over 270 patents globally. The patent is expected to provide long-term protection in Europe.

FibroBiologics (FBLG) presented preclinical data at the North American Spine Society Annual Meeting, showing statistically significant improvements in disc height for all fibroblast-treated groups in a 12-week rabbit model. The FSdC spheroid group showed the highest percent disc height index at 80.7% compared to 71.8% in controls. The company develops treatments using fibroblast cells and holds over 270 patents.

FibroBiologics (NASDAQ:FBLG) received a Notice of Acceptance for an Australian patent covering methods to regenerate cartilage cells and repair degenerated spinal discs. The patent involves using fibroblasts, platelet-rich plasma, and nucleus pulposus components. The company holds over 270 patents globally across various clinical areas. This development may impact FBLG's intellectual property portfolio and potential treatments.

FibroBiologics issued a $1.2M convertible debenture to Peak One, including 125,000 commitment shares. The debenture, sold at a 15% discount, has 0% interest but converts at $0.78/share if default occurs, with up to 18% interest and 120% acceleration. The company can redeem at par in 2027 if no default happens, with Nasdaq rules limiting ownership and share exchange. Proceeds from future financings or asset sales may repay the debenture.

FibroBiologics, Inc. (FBLG) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On October 7, 2026, FibroBiologics, Inc. (the “Company”) entered into a securities purchase agreement (the “SPA”) with Peak One Opportunity Fund, L.P. (“Peak One”), pursuant to which the Company agreed to issue to Peak One, in

FibroBiologics Inc. (FBLG) filed a U.S. patent for a cell-based platform that produces therapeutic peptides continuously in the body, potentially replacing GLP-1 injections for weight loss and diabetes. The technology targets multiple conditions and uses various cell types. Shares were down 1.28% premarket.

FibroBiologics, Inc. (FBLG) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Exhibit 99.1 FibroBiologics Announces Closing of $0.5 Million Private Placement with Chief Scientific Officer HOUSTON, September 17, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics" or the “Company”), a clinical-stage biotechnology company with 270+ pate

FibroBiologics (FBLG) raised $500,000 via a private placement to its Chief Scientific Officer, including 298,508 shares and warrants. The offering price was $1.675 per share and warrant, matching the Nasdaq closing price plus a premium. Proceeds will be used for general corporate purposes. The warrants are exercisable immediately and expire in five years.